Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 4, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2014-04-28
DOI
10.3389/fonc.2014.00090
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma
- (2013) Krishna P.L. Bhat et al. CANCER CELL
- Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma
- (2013) R. Shao et al. CARCINOGENESIS
- The NF-κB RelB Protein Is an Oncogenic Driver of Mesenchymal Glioma
- (2013) Dong Whan Lee et al. PLoS One
- Prominin 1/CD133 Endothelium Sustains Growth of Proneural Glioma
- (2013) Bi-Sen Ding et al. PLoS One
- Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients
- (2012) Maurizio Salvati et al. JOURNAL OF NEUROSURGERY
- Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch
- (2012) Desiree H. Floyd et al. NEURO-ONCOLOGY
- Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma
- (2012) Xinlong Ma et al. NEURO-ONCOLOGY
- A Complex of Nuclear Factor I-X3 and STAT3 Regulates Astrocyte and Glioma Migration through the Secreted Glycoprotein YKL-40
- (2011) Sandeep K. Singh et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of Glioblastoma
- (2011) Ralph A. Francescone et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Serum YKL-40 following resection for cerebral glioblastoma
- (2011) Daniela Bernardi et al. JOURNAL OF NEURO-ONCOLOGY
- Autocrine Endothelin-3/Endothelin Receptor B Signaling Maintains Cellular and Molecular Properties of Glioblastoma Stem Cells
- (2011) Y. Liu et al. MOLECULAR CANCER RESEARCH
- A YKL-40-Neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in Cancers
- (2011) M. Faibish et al. MOLECULAR CANCER THERAPEUTICS
- A multigene predictor of outcome in glioblastoma
- (2011) H. Colman et al. NEURO-ONCOLOGY
- Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas
- (2011) F. M. Iwamoto et al. NEURO-ONCOLOGY
- Resveratrol represses YKL-40 expression in human glioma U87 cells
- (2010) Wei Zhang et al. BMC CANCER
- A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry
- (2010) S. El Hallani et al. BRAIN
- Association between YKL-40 and adult primary astrocytoma
- (2010) Wei Zhang et al. CANCER
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells
- (2010) Bo Mi Ku et al. INTERNATIONAL JOURNAL OF CANCER
- Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma
- (2010) Hideho Okada et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas
- (2010) Manila Antonelli et al. JOURNAL OF NEURO-ONCOLOGY
- Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors
- (2009) Qinghai Liu et al. JOURNAL OF NEURO-ONCOLOGY
- No association of (−131C→G) variant of CHI3L1 gene with risk of glioblastoma and prognosis
- (2009) Blandine Boisselier et al. JOURNAL OF NEURO-ONCOLOGY
- YKL-40, a secreted glycoprotein, promotes tumor angiogenesis
- (2009) R Shao et al. ONCOGENE
- Diurnal, Weekly, and Long-Time Variation in Serum Concentrations of YKL-40 in Healthy Subjects
- (2008) J. S. Johansen et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Selective repression of YKL-40 by NF-κB in glioma cell lines involves recruitment of histone deacetylase-1 and -2
- (2008) Krishna P. Bhat et al. FEBS LETTERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started